Table of Contents

---

---

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 6, 2002

GERON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		0-20859		75-2287752
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

230 Constitution Drive Menlo Park, California				94025
(Address of principal executive offices)				(Zip Code)

(650) 473-7700

N/A

---

---

 

---

	Item 5. Other Events.
	Item 7. Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

---

Table of Contents

Item 5. Other Events.

On March 6, 2002, Geron Corporation, a Delaware corporation (the “Company”), announced that it has acquired patents related to oligonucleotides containing phosphoramidate backbone linkages from Lynx Therapeutics, Inc.

The Company’s press release announcing the acquisition is filed as an exhibit to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the document filed as an exhibit hereto.

2

---

Table of Contents

Item 7. Exhibits.

Exhibits
99.1		Press Release dated March 6, 2002.

3

---

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		GERON CORPORATION
Date: March 8, 2002		By:		/s/ William D. Stempel
		Name:		William D. Stempel
		Title:		Vice President and General Counsel

4

---

Table of Contents

EXHIBIT INDEX

Exhibits
99.1		Press Release dated March 6, 2002.

5